Asher Bio
Last verified 2026-09-25. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $5.0Mattributed |
|---|---|
| Latest round | series-a, $5.0M, 2024-09-15attributed |
| Founded | 2018 |
| Headquarters | San Carlos |
| Industry | healthcare |
| Stage | series-a |
| Website | asherbio.com |
Asher Bio develops cis-targeted immunotherapies that selectively activate specific immune cells to fight cancer more effectively. The treatment addresses patients with various cancers by engaging two molecules on the same cell, activating only when the antigen is present. It offers selectivity with optimized efficacy and minimized toxicity.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-09-15 | series-a | $5.0M | yc |
Detected tech stack
Nginx, WordPress, Yoast SEO 27.6, Google Analytics, Google Hosted Libraries, Google Tag Manager, FancyBox, jQuery Migrate 3.4.1, jQuery UI 1.9.1, DoubleClick Floodlight, CookieYes 3.5.0, WP Engine
Provenance
| Fact | Status | Basis |
|---|---|---|
| Series A, $5.0M | attributed | yc named as publisher. No document URL on file. |
| Total raised $5.0M | attributed | yc named as publisher. No document URL on file. |
| Company existence | sourced | Y Combinator named as publisher. Document, retrieved 2026-09-17. |
| Description | self-reported | asherbio.com, read 2026-09-25 |
Change history
| Date | Fact | Change | Basis |
|---|---|---|---|
| 2026-09-24Existence: self-reported → sourced, Y Combinator, document, retrieved 2026-09-17 | Existence | self-reported → sourced | Y Combinator, document, retrieved 2026-09-17 |
Records begin 2026-09-24. All changes